Medexus Pharmaceuticals Inc (MDP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 852 | 996 | 824 | 59 | 59 |
| Accounts receivable | -3,419 | 3,657 | -2,172 | 39 | -382 |
| Accounts payable and accrued liabilities | 2,289 | -2,615 | -660 | N/A | 252 |
| Other Working Capital | -556 | 982 | -1,828 | 2,449 | 89 |
| Other Operating Activity | 678 | -3,520 | 2,782 | -2,696 | -271 |
| Operating Cash Flow | $-156 | $-499 | $-1,055 | $-149 | $-254 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -28 | -27 | 0 | 0 | 0 |
| Net Acquisitions | N/A | 58 | -16,944 | N/A | N/A |
| Purchase Sale Intangibles | -467 | 404 | -556 | -258 | -6 |
| Investing Cash Flow | $-495 | $435 | $-17,500 | $-258 | $-6 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 620 | 30,836 | N/A | N/A |
| Debt Repayment | -84 | -102 | -5,088 | N/A | N/A |
| Common Stock Issued | N/A | 295 | 14,647 | 46 | 0 |
| Common Stock Repurchased | -502 | N/A | N/A | N/A | N/A |
| Other Financing Activity | 0 | -57 | -2,820 | 0 | 0 |
| Financing Cash Flow | $-586 | $756 | $37,576 | $46 | $0 |
| Exchange Rate Effect | -143 | -81 | 131 | N/A | N/A |
| Beginning Cash Position | 22,247 | 21,210 | 2,057 | 2,529 | 2,744 |
| End Cash Position | 20,867 | 21,873 | 21,210 | 2,169 | 2,484 |
| Net Cash Flow | $-1,237 | $691 | $19,021 | $-360 | $-259 |
| Free Cash Flow | |||||
| Operating Cash Flow | -156 | -499 | -1,055 | -149 | -254 |
| Capital Expenditure | -495 | N/A | -556 | -258 | -6 |
| Free Cash Flow | -651 | -499 | -1,611 | -406 | -259 |